Skip to content
← All treatment topics

TREATMENT READING

AIDS-Related Lymphoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

Health professional

Treatment Option Overview for AIDS-Related Lymphoma

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 18, 2024. Captured 2026-09-09.

The treatment of patients with AIDS-related lymphomas presents the challenge of integrating therapy appropriate for the stage and histological subset of malignant lymphoma with the limitations imposed by HIV infection.[1] In addition to antitumor therapy, essential components of an optimal non-Hodgkin lymphoma treatment strategy include:[2,3]

Sources: 1 · 2 · 3

Highly active antiretroviral therapy.

Prophylaxis for opportunistic infections.

Rapid recognition and treatment of intercurrent infections.

Patients with HIV positivity and underlying immunodeficiency have poor bone marrow reserve, which compromises the potential for drug dose intensity. Intercurrent opportunistic infection is a risk that may also lead to a decrease in drug delivery. Furthermore, chemotherapy itself compromises the immune system and increases the likelihood of opportunistic infection.

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment of AIDS-Related Peripheral/Systemic Lymphoma

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 18, 2024. Captured 2026-09-09.

The treatment of AIDS-related lymphomas involves overcoming several problems. These are all aggressive lymphomas, which by definition are diffuse large cell/immunoblastic lymphoma or small noncleaved cell lymphoma (Burkitt lymphoma). These lymphomas frequently involve the bone marrow and central nervous system (CNS) and, therefore, are usually in an advanced stage. In addition, the immunodeficiency of AIDS and the leukopenia that is commonly seen with HIV infection makes the use of immunosuppressive chemotherapy challenging.

The introduction of highly active antiretroviral therapy (HAART) has led to a marked reduction in opportunistic infections, prolonged survival with HIV infection, and a median overall survival (OS) for patients with AIDS-related lymphoma that is comparable with the outcome in the nonimmunosuppressed population.[1-7][Level of evidence C3] The use of HAART has also allowed standard-dose and even intensive chemotherapy regimens to be given with reasonable safety to patients with AIDS-related lymphomas, which is comparable with the outcome in patients without HIV.[1-10]

Sources: 1 · 7 · Level of evidence C3 · 1 · 10

Several prospective nonrandomized trials and pooled individual data from 19 prospective trials that included 1,546 patients show that the addition of rituximab to combination chemotherapy improves the complete response rate, progression-free survival, and OS.[3-6][Level of evidence C3] Several other prospective nonrandomized trials and the pooled individual data from the same 1,546 patients also show that infusional EPOCH (infusional etoposide, infusional vincristine, infusional doxorubicin, cyclophosphamide, and prednisone) produced better outcomes than did CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) (hazard ratioOS, 0.33; P = .03).[3,6,7][Level of evidence C3] Concurrent use of HAART with the infusional EPOCH regimen is controversial; one group advocated for HAART after completion of chemotherapy,[7] while others allowed concurrent therapy.[6]

Sources: 3 · 6 · Level of evidence C3 · 3 · 6 · 7 · Level of evidence C3 · 7 · 6

For patients with Burkitt lymphoma, dose-modified regimens such as R-CODOX (cyclophosphamide, doxorubicin, vincristine, methotrexate, cytarabine and rituximab)-M/IVAC (ifosfamide, etoposide, and high-dose cytarabine) or R-EPOCH (etoposide, prednisone, vincristine, and doxorubicin in combination with rituximab) have shown good results with concurrent or sequential HAART.[7,11,12]

Sources: 7 · 11 · 12

Patients at risk of subsequent CNS involvement include those with bone marrow involvement or those with EBV identified in the primary tumor or in the cerebrospinal fluid (i.e., by polymerase chain reaction).[13,14] Intrathecal chemotherapy is usually considered for patients who are at higher risk of CNS involvement.

Sources: 13 · 14

Highly selected patients with resistant or relapsed lymphoma after first-line chemotherapy and with continued responsiveness to HAART underwent second-line chemotherapy followed by high-dose therapy and autologous peripheral stem cell transplant. Long-term survivors have been reported anecdotally for these highly selected patients who relapsed.[15-18][Level of evidence C3]

Sources: 15 · 18 · Level of evidence C3

Health professional

Treatment of AIDS-Related Primary Central Nervous System Lymphoma

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 18, 2024. Captured 2026-09-09.

As with other AIDS-related lymphomas, primary central nervous system (CNS) lymphoma (PCNSL) is an aggressive B-cell neoplasm, either diffuse large B-cell or diffuse immunoblastic non-Hodgkin lymphoma (a subtype of diffuse large B-cell lymphoma). AIDS-related PCNSL has been reported to have a 100% association with Epstein-Barr virus (EBV).[1] These patients usually have evidence of low CD4-positive T lymphocyte counts, high HIV viral load, severe debilitation, and focal neurological symptoms such as seizures, changes in mental status, and paralysis.

Sources: 1

Computed tomographic scans show contrast-enhancing mass lesions that may not always be distinguished from other CNS diseases, such as toxoplasmosis, that occur in patients with AIDS.[2] Magnetic resonance imaging studies using gadolinium contrast may be a more useful initial diagnostic tool in differentiating lymphoma from cerebral toxoplasmosis or progressive multifocal leukoencephalopathy. Lymphoma tends to present with large lesions, which are enhanced by gadolinium. In cerebral toxoplasmosis, ring enhancement is very common, lesions tend to be smaller, and multiple lesions are seen.[3-5] Use of positron emission scanning has demonstrated an improved ability to distinguish PCNSL from toxoplasmosis.[6,7] PCNSL has an increased uptake while toxoplasmosis lesions are metabolically inactive. Antibodies against toxoplasmosis may also be very useful because most cerebral toxoplasmosis occurs as a consequence of reactivity of a previous infection. If the immunoglobulin G titer is less than 1:4, the disease is unlikely to be toxoplasmotic. A lumbar puncture may be useful to detect as many as 23% of patients with malignant cells in their cerebrospinal fluid (CSF). Evaluating the CSF for EBV DNA may be a useful lymphoma-specific tool because EBV is present in all patients with PCNSL. Despite the many evaluations, however, most patients with PCNSL require a pathological diagnosis.[8-10] Diagnosis is made by biopsy. Sometimes, a biopsy is attempted only after failure of antibiotics for toxoplasmosis, which will produce clinical and radiographic improvement within 1 to 3 weeks in patients with cerebral toxoplasmosis.[11]

Sources: 2 · 3 · 5 · 6 · 7 · 8 · 10 · 11

Radiation therapy alone has usually been used in this group of patients. With doses in the range of 35 Gy to 40 Gy, median duration of survival has been only 72 to 119 days.[2,12,13] Survival is longer in younger patients with better performance status and the absence of opportunistic infection.[14] In the highly active antiretroviral therapy (HAART) era, a median survival of 18 months has been seen with radiation therapy alone.[15] An anecdotal report using HAART and high-dose methotrexate for patients with AIDS-related PCNSL showed a median survival that had not been reached with a median follow-up of 27 months.[16] Most patients respond to treatment by showing partial improvement in neurological symptoms. Autopsies have revealed that these patients die of opportunistic infections as well as tumor progression. Treatment of these patients is also complicated by other AIDS-related CNS infections, including subacute AIDS encephalitis, cytomegalovirus encephalitis, and toxoplasmosis encephalitis. Spontaneous remissions have been reported after HAART.[17]

Sources: 2 · 12 · 13 · 14 · 15 · 16 · 17

For patients · General Information About AIDS-Related Lymphoma

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

The prognosis and treatment options depend on the following:

Sources: prognosis

The stage of the cancer.

Sources: stage

The age of the patient.

The number of CD4 lymphocytes (a type of white blood cell) in the blood.

Sources: CD4 lymphocytes

The number of places in the body lymphoma is found outside the lymph system.

Whether the patient has a history of intravenous (IV) drug use.

Sources: intravenous · drug use

The patient's ability to carry out regular daily activities.

Sources: regular daily activities

For patients · Stages of AIDS-Related Lymphoma

For treatment, AIDS-related lymphomas are grouped based on where they started in the body, as follows:

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

For patients · Stages of AIDS-Related Lymphoma / For treatment, AIDS-related lymphomas are grouped based on where they started in the body, as follows:

Peripheral/systemic lymphoma

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

Lymphoma that starts in the lymph system or elsewhere in the body, other than the brain, is called peripheral/systemic lymphoma. It may spread throughout the body, including to the brain or bone marrow. It is often diagnosed in an advanced stage.

Sources: Lymphoma · lymph system · bone marrow

For patients · Stages of AIDS-Related Lymphoma / For treatment, AIDS-related lymphomas are grouped based on where they started in the body, as follows:

Primary CNS lymphoma

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

Primary CNS lymphoma starts in the central nervous system (brain and spinal cord). It is linked to the Epstein-Barr virus. Lymphoma that starts somewhere else in the body and spreads to the central nervous system is not primary CNS lymphoma.

Sources: Primary CNS lymphoma · central nervous system · Lymphoma

For patients

Treatment Option Overview

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

There are different types of treatment for patients with AIDS-related lymphoma.

Treatment of AIDS-related lymphoma combines treatment of the lymphoma with treatment for AIDS.

The following types of treatment are used:

The following types of treatment are used:

Chemotherapy

Radiation therapy

High-dose chemotherapy with stem cell transplant

Targeted therapy

New types of treatment are being tested in clinical trials.

Treatment for AIDS-related lymphoma may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up tests may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with AIDS-related lymphoma.

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

Different types of treatment are available for patients with AIDS-related lymphoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: AIDS-related · lymphoma · standard · clinical trials · research study · cancer

For patients · Treatment Option Overview

Treatment of AIDS-related lymphoma combines treatment of the lymphoma with treatment for AIDS.

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

Patients with AIDS have weakened immune systems and treatment can cause the immune system to become even weaker. For this reason, treating patients who have AIDS-related lymphoma is difficult and some patients may be treated with lower doses of drugs than lymphoma patients who do not have AIDS.

Sources: AIDS · immune systems · doses · drugs

Highly active antiretroviral therapy (HAART) is used to lessen the damage to the immune system caused by HIV. Treatment with HAART may allow some patients with AIDS-related lymphoma to safely receive anticancer drugs in standard or higher doses. In these patients, treatment may work as well as it does in lymphoma patients who do not have AIDS. Medicine to prevent and treat infections, which can be serious, is also used.

Sources: Highly active antiretroviral therapy · HIV · Medicine · infections

For more information about AIDS and its treatment, see the AIDSinfo website.

Sources: AIDSinfo website

For patients · Treatment Option Overview

The following types of treatment are used:

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid (intrathecal chemotherapy), an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is treatment using more than one anticancer drug.

Sources: Chemotherapy · cells · injected · vein · systemic chemotherapy · cerebrospinal fluid · intrathecal chemotherapy · organ · cavity · abdomen · regional chemotherapy · Combination chemotherapy

Intrathecal chemotherapy may be used in patients who are more likely to have lymphoma in the central nervous system (CNS).

Sources: central nervous system

Chemotherapy is used in the treatment of AIDS-related peripheral/systemic lymphoma. It is not yet known whether it is best to give HAART at the same time as chemotherapy or after chemotherapy ends.

Sources: systemic

Colony-stimulating factors are sometimes given together with chemotherapy. This helps lessen the side effects chemotherapy may have on the bone marrow.

Sources: Colony-stimulating factors · side effects · bone marrow

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: Radiation therapy · x-rays · radiation · External radiation therapy

For patients · Treatment Option Overview / The following types of treatment are used:

High-dose chemotherapy with stem cell transplant

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.

Sources: blood · Stem cell transplant · Stem cells · infusion

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do.

Sources: Targeted therapy · drugs

Monoclonal antibodies: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. These may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Rituximab is used in the treatment of AIDS-related peripheral/systemic lymphoma.

Sources: Monoclonal antibodies · antibodies · toxins · Rituximab

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview

Treatment for AIDS-related lymphoma may cause side effects.

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of AIDS-Related Peripheral/Systemic Lymphoma

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of AIDS-related peripheral/systemic lymphoma may include the following:

Sources: AIDS-related · systemic · lymphoma

Combination chemotherapy with or without targeted therapy.

Sources: Combination chemotherapy · targeted therapy

High-dose chemotherapy and stem cell transplant, for lymphoma that has not responded to treatment or has come back.

Sources: High-dose chemotherapy · stem cell transplant · responded

Intrathecal chemotherapy for lymphoma that is likely to spread to the central nervous system (CNS).

Sources: Intrathecal chemotherapy · central nervous system

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of AIDS-Related Primary Central Nervous System Lymphoma

Source: AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 17, 2023. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of AIDS-related primary central nervous system lymphoma may include the following:

Sources: AIDS-related · primary central nervous system lymphoma

External radiation therapy.

Sources: External radiation therapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

NCT00006436 · COMPLETED · phase2

Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse

ClinicalTrials.gov record

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

NCT02911142 · ACTIVE NOT RECRUITING · phase1, phase2

Primary Effusion Lymphoma, B-Cell Neoplasm

ClinicalTrials.gov record

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

NCT05510908 · COMPLETED · Phase not reported

HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy

ClinicalTrials.gov record

Disease and treatment settings